✦ LIBER ✦

Phase II studies using electroporation therapy in patients with recurrent head and neck cancer: a safe and active treatment approach

✍ Scribed by P. Goldfarb; F. Hill

Book ID: 117667622
Publisher: Elsevier Science
Year: 1999
Tongue: English
Weight: 156 KB
Volume: 35
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(99)81079-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II study of sunitinib in patient

A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer

✍ George Fountzilas; Anna Fragkoulidi; Anna Kalogera-Fountzila; Martha Nikolaidou; 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 639 KB

Results of a randomised phase II study c

Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer

✍ E. Guardiola; F. Peyrade; L. Chaigneau; D. Cupissol; X. Tchiknavorian; E. Bompas 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 171 KB

Phase II Study of Weekly Docetaxel and C

Phase II Study of Weekly Docetaxel and Cisplatin in Patients With Advanced Recurrent and Metastatic Head and Neck Cancer

✍ Orlando Guntinas-Lichius; Stefan Appenrodt; Florian Veelken; Barbara Krug 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 222 KB

A phase II study of piritrexim in combin

A phase II study of piritrexim in combination with methotrexate in recurrent and metastatic head and neck cancer

✍ Everett E. Vokes; Isaiah W. Dimery; Charlotte D. Jacobs; Daniel Karp; Arturo Mol 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 468 KB 👁 2 views

Thirty patients with recurrent and/or metastatic head and neck cancer were treated with sequentially administered methotrexate (MTX) and piritrexim (PTX). The treatment schedule consisted of intravenous (IV) MTX (50 mg/m') administered on day 1 and oral PTX (75 mg/mz) administered twice daily on day

A phase II trial of subcutaneous amifost

A phase II trial of subcutaneous amifostine and radiation therapy in patients with head and neck cancer

✍ Pramila Rani Anné; Walter J. Curran Jr 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 125 KB

A phase II study of piritrexim in patien

A phase II study of piritrexim in patients with advanced squamous head and neck cancer

✍ Wu-Ching Uen; Andrew T. Huang; Robert Mennel; Stephen E. Jones; Monica B. Spauld 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 347 KB 👁 3 views

Piritrexim (PTX) is a newly developed lipid-soluble folate antagonist that crosses the cell membrane by a simple, rapid, carrier-independent diffusion process. A Phase II study was conducted to evaluate the activity of PTX in 34 patients with previously chemotherapy-naive squamous cell cancer of the